We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Astria Therapeutics Inc (ATXS) USD0.001

Sell:$11.53 Buy:$13.62 Change: $0.36 (2.77%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Change: $0.36 (2.77%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Change: $0.36 (2.77%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).

Contact details

75 State Street, Suite 1400
United States
+1 (617) 3491971

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$762.59 million
Shares in issue:
54.67 million
United States
US dollar

Key personnel

  • Jill Milne
    President, Chief Executive Officer, Co-Founder, Director
  • Noah Clauser
    Chief Financial Officer
  • John Ruesch
    Senior Vice President- Pharmaceutical Sciences and Technical Operations
  • Benjamin Harshbarger
    Chief Legal Officer
  • Andrew Komjathy
    Chief Commercial Officer
  • Andrea Matthews
    Chief Business Officer
  • Christopher Morabito
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.